Robot model
mBos TKA System
The Monogram mBos TKA System is Monogram's robotic total-knee-arthroplasty platform, recorded in the surgical form factor as the autonomy-boundary case of the orthopedic sub-cohort: unlike the AI-augmented surgeon-controlled systems Stryker Mako, Smith+Nephew CORI, and Zimmer Biomet ROSA, where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with the robotic arm executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. It pairs CT-based pre-operative planning and predictive navigation with a robotic arm, built on a KUKA arm, that executes optimized cutting and insertion paths for Monogram's mPress press-fit implants. The system received FDA 510(k) clearance on March 17, 2025, although the precise cleared indication wording and the K-number could not be independently verified and the semi-autonomous characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter, which Monogram's own clearance release described more softly as robotic-assisted TKA. A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure was performed on July 26, 2025 at Krishna Shalby Hospital in Ahmedabad, India under an India CDSCO approval for a 102-procedure investigation, not under US FDA, as a single index case without verified peer-reviewed outcomes. Made by Monogram Technologies, founded in 2015 as Monogram Orthopaedics by orthopedic surgeon Dr. Doug Unis, who is chief medical officer and founder rather than chief executive, with Benjamin Sexson as the pre-acquisition CEO, and renamed Monogram Technologies in May 2024 trading on NASDAQ as MGRM, the company was acquired by Zimmer Biomet with the deal closing October 7, 2025 at about 168 million dollars enterprise value plus contingent value rights, making Monogram a Zimmer Biomet subsidiary with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records the system at research maturity because it is cleared but pre-commercial with no units sold, and its headline fully-autonomous capability remains in development.
mBos TKA System is a surgical robot built by Monogram Technologies.
Machine-readable surfaces
- Markdown mirror: /models/monogram-mbos.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/078e765e-b40f-43c4-a23e-50643a23484e
- Data documentation: /data
- Form factor
- surgical
- Maturity stage
- research
- Lifecycle
- active
- Deployments
- 0
- ID
078e765e-b40f-43c4-a23e-50643a23484e
Specs
- notes
- [object Object],[object Object],[object Object],[object Object],[object Object]
- specs
- Monogram mBos TKA System: robotic total-knee-arthroplasty platform. CT-based patient-specific pre-operative planning + AI/predictive navigation + a robotic arm (built on a KUKA arm) that EXECUTES the bone cuts and insertion paths for Monogram's mPress press-fit implants (separately FDA-cleared). The cleared system is SEMI-AUTONOMOUS: the robot performs the cut under AI control within a surgeon-approved CT-based plan and active surgeon supervision - distinct from the surgeon-hands-on Mako/CORI/ROSA. A separate FULLY-autonomous, hands-free, foot-pedal-activated saw-based version is NOT FDA cleared and remains in development (~late 2027/2028). Made by Monogram Technologies, a Zimmer Biomet subsidiary since Oct 2025.
- formFactor
- surgical (robotic total-knee-arthroplasty; AUTONOMY-BOUNDARY case - AI-primary semi-autonomous bone-cutting, distinct from surgeon-controlled assistance)
Supply chain
No verified supply relationships on file. Supply-chain coverage is being added across the registry; check back as the seed populates this model’s suppliers.
Suppliers appear here when verified with at least two strong sources (maker-official / IR / regulatory / standards-body / verified tier-2). Sources are append-only; corrections add new sources rather than rewrite history.
Sources (7)
- https://www.biospace.com/press-releases/monogram-technologies-announces-fda-510k-clearance-for-the-monogram-mbostm-tka-system
- https://www.prnewswire.com/news-releases/zimmer-biomet-completes-acquisition-of-monogram-technologies-302577035.html
- https://www.globenewswire.com/news-release/2025/07/29/3123344/0/en/Monogram-Technologies-Announces-World-s-First-Fully-Autonomous-Saw-Based-Robotic-Knee-Replacement-Surgery.html
- https://www.medtechdive.com/news/zimmer-why-acquire-monogram-robotics/753204/
- https://www.globenewswire.com/news-release/2025/05/14/3081555/0/en/Monogram-Technologies-Reports-First-Quarter-2025-Financial-Results.html
- https://www.sec.gov/Archives/edgar/data/0001769759/000110465925097530/tm2527971d1_ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/0001136869/000119312525158442/d76564dex992.htm
Common questions
- What is mBos TKA System?
- The Monogram mBos TKA System is Monogram's robotic total-knee-arthroplasty platform, recorded in the surgical form factor as the autonomy-boundary case of the orthopedic sub-cohort: unlike the AI-augmented surgeon-controlled systems Stryker Mako, Smith+Nephew CORI, and Zimmer Biomet ROSA, where the surgeon makes the cuts, the cleared mBos is semi-autonomous, with the robotic arm executing the bone cuts itself under AI control within a surgeon-approved, patient-specific CT-based plan and active surgeon supervision. It pairs CT-based pre-operative planning and predictive navigation with a robotic arm, built on a KUKA arm, that executes optimized cutting and insertion paths for Monogram's mPress press-fit implants. The system received FDA 510(k) clearance on March 17, 2025, although the precise cleared indication wording and the K-number could not be independently verified and the semi-autonomous characterization is sourced to Zimmer Biomet and trade coverage rather than the FDA letter, which Monogram's own clearance release described more softly as robotic-assisted TKA. A separate fully-autonomous, hands-free, saw-based version is not FDA cleared and remains in development, targeted around late 2027 or 2028; its first live-patient procedure was performed on July 26, 2025 at Krishna Shalby Hospital in Ahmedabad, India under an India CDSCO approval for a 102-procedure investigation, not under US FDA, as a single index case without verified peer-reviewed outcomes. Made by Monogram Technologies, founded in 2015 as Monogram Orthopaedics by orthopedic surgeon Dr. Doug Unis, who is chief medical officer and founder rather than chief executive, with Benjamin Sexson as the pre-acquisition CEO, and renamed Monogram Technologies in May 2024 trading on NASDAQ as MGRM, the company was acquired by Zimmer Biomet with the deal closing October 7, 2025 at about 168 million dollars enterprise value plus contingent value rights, making Monogram a Zimmer Biomet subsidiary with commercialization alongside Zimmer Biomet implants targeted for early 2027. The registry records the system at research maturity because it is cleared but pre-commercial with no units sold, and its headline fully-autonomous capability remains in development.
- Who makes mBos TKA System?
- mBos TKA System is made by Monogram Technologies, based in Austin, Texas, USA, founded in 2015.
- Where is mBos TKA System deployed?
- No verified deployments of mBos TKA System are currently on the DEPLOY registry. DEPLOY records deployments only when verified at a named site with a primary source; absence may reflect pre-deployment, research, or manufacturer-internal use.
- What is mBos TKA System's maturity stage?
- mBos TKA System is at the research stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Research stage means active development without commercial deployments on file.